Medical Weight Loss

Patient on Scale

The U.S. Food and Drug Administration approved semaglutide injection (2.4 mg once weekly) for chronic weight management in adults with obesity or overweight with at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol), for use in addition to a reduced calorie diet and increased physical activity. Semaglutide works by mimicking a hormone called glucagon-like peptide-1 (GLP-1) that targets areas of the brain that regulate appetite and food intake. The medication dose must be increased gradually over 16 to 20 weeks to 2.4 mg once weekly to reduce gastrointestinal side effects. 

In a placebo-controlled trial of adults without diabetes, individuals who received semaglutide  lost an average of 12.4% of their initial body weight compared to individuals who received placebo. 

fda_approval.jpg